e-learning
resources
Berlin 2008
Monday, 06.10.2008
Community-acquired pneumonia: prognosis, complications and prevention
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Influenza and pneumoccocal vaccination protect against all cause mortality in COPD
S. Schembri, S. Morant, J. Winter, T. MacDonald (Dundee, United Kingdom)
Source:
Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention
Session:
Community-acquired pneumonia: prognosis, complications and prevention
Session type:
Thematic Poster Session
Number:
2261
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Schembri, S. Morant, J. Winter, T. MacDonald (Dundee, United Kingdom). Influenza and pneumoccocal vaccination protect against all cause mortality in COPD. Eur Respir J 2008; 32: Suppl. 52, 2261
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Influenza and pneumococcal vaccination in patients with COPD
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Influenza vaccination in COPD
Source: International Congress 2019 – Vaccines against respiratory infections
Year: 2019
Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects
Source: Eur Respir J 2005; 26: 1086-1091
Year: 2005
Influenza vaccination is associated with reduced severity of community-acquired pneumonia
Source: Eur Respir J 2011; 37: 147-153
Year: 2011
Should pneumococcal vaccines be used to prevent LRTI?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009
Perception and uptake of the influenza and pneumococcal vaccinations in patients with COPD
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008
Influenza and pneumococcal vaccination
Source: International Congress 2017 – State of the art session: "Respiratory infections"
Year: 2017
Influenza vaccination and its relation with LRTI
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009
Efficacy of influenza and pneumococcal vaccinations among patients with COPD
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007
Pneumococcal and influenza vaccination
Source: Eur Respir Monogr 2014; 63: 266-284
Year: 2014
Additive preventive effect of influenza and pneumococcal vaccines in elderly persons
Source: Eur Respir J 2004; 23: 363-368
Year: 2004
Outcome of influenza vaccination in elderly with pneumonia
Source: International Congress 2019 – Airway infection in COPD
Year: 2019
Societal perspective and challenges of influenza and pneumococcal vaccination in patients at risk of respiratory complications
Source: Annual Congress 2008 - Why vaccinate patients with chronic respiratory conditions? Today and tomorrow's perspectives
Year: 2008
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil
Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma
Year: 2013
Pneumococcal and influenza vaccination
Source: Respipedia Article
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept